Tag Archive for ‘pancreatic cancer’

Role of radiation in the treatment of pancreatic adenocarcinoma in the neoadjuvant setting

Summarizes the findings of recent studies examining the role of radiation therapy in the treatment of pancreatic ductal adenocarcinoma in the contemporary neoadjuvant setting.

ALLIANCE A021806 examines perioperative vs. adjuvant chemotherapy for resectable pancreatic cancer

Summarizes comparative study data to determine the utility of delivering perioperative and adjuvant chemotherapy to cancer patients.

New trial aims to settle debate on the intensity of pancreatic cyst surveillance

Pancreatic cystic neoplasms occur in up to 20 percent of the U.S. adult population, and the incidence increases with more advanced age.1 In recent years, the prevalence of cystic neoplasms of the pancreas appears to be increasing as more patients undergo cross-sectional imaging in both the ambulatory and emergency setting. A recent study of patients […]

ACS CRP

Ga-68 imaging changes clinical management of GI and pancreatic neuroendocrine tumors

Ga-68 positron emission tomography has improved the clinical management of gastrointestinal and pancreatic neuroendocrine tumors, and multiple studies are ongoing to define its optimal role in clinical practice.

 

NCDB logo

Neoadjuvant and perioperative chemotherapy for localized pancreatic cancer: Leveraging small and large databases in the absence of Level 1 evidence

In the rapidly evolving clinical paradigms for localized pancreatic cancer, a combination of Level 1 data and large and small database studies can inform disease management.

From Residency to Retirement

Databases: Where math meets medicine

Balancing statistical relevance with clinician experience leads to innovative approaches to patient care.

ACS CRP

Modified FOLFIRINOX is superior to gemcitabine as adjuvant therapy for resected pancreatic cancer: The PRODIGE 24/CCTG PA6 Trial

The study design and findings of the PRODIGE 24/CCTG PA6 Trial are outlined, which showed improved survival with modified FOLFIRINOX for resected pancreatic cancer patients.

JACS

Coming next month in JACS, and online now: Distal cholangiocarcinoma and pancreas cancer

This news brief highlights a JACS article that examines the results of a distal cholangiocarcinoma and pancreatic cancer multi-institution study.

Figure 1. Schema for SWOG Trial 1505

Two studies pave the way for preoperative therapy in pancreatic cancer patients

Pancreatic cancer is the fourth-most common cause of cancer-related death in the U.S. and is predicted to soon be the third-leading cause. Surgical resection with pancreatectomy has historically been viewed as offering the only chance for cure. However, achieving negative margins at surgery can be difficult, with positive surgical margins found in as many as […]

figure 1

Improving resection rates in borderline resectable pancreatic cancer: Pilot study shows favorable results

The clinical importance of the Alliance A021101 cooperative group study as well as the design of the trial itself are the focus of this month’s column.

Borderline resectable pancreatic cancer: Pushing the technical limits of surgery

This column discusses how multimodality therapy, including surgical resection, now represents a potential route to long-term survival for a group of patients with so-called “borderline resectable” cancers.

Contact

Bulletin of the American College of Surgeons
633 N. Saint Clair St.
Chicago, IL 60611

Archives

Download the Bulletin App

Apple Store
Get it on Google Play
Amazon store